CLYM (Climb Bio) Interest Expense: $0.00 Mil (TTM As of Mar. 2026)


CLYM Climb Bio Inc CLYM
22 GF Score
Price $12.90
! 3 Warning Signs
View Full Analysis

What is Climb Bio Interest Expense?

Climb Bio CLYM -2.93% 22 Interest Expense is $0.00 Mil as of Mar. 2026. GuruFocus rates CLYM with a GF Score™ of 22/100. The stock has 3 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Climb Bio's interest expense for the three months ended in Mar. 2026 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Climb Bio's Operating Income for the three months ended in Mar. 2026 was $ -15.21 Mil. Climb Bio's Interest Expense for the three months ended in Mar. 2026 was $ 0.00 Mil. GuruFocus does not calculate Climb Bio's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Climb Bio  (NAS:CLYM) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Climb Bio's Interest Expense for the three months ended in Mar. 2026 was $0.00 Mil. Its Operating Income for the three months ended in Mar. 2026 was $-15.21 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was $0.22 Mil.

Climb Bio's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

GuruFocus does not calculate Climb Bio's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Climb Bio Inc has enough cash to cover all of its debt. Its financial situation is stable.

Climb Bio Interest Expense Historical Data

* Premium members only.

The historical data trend for Climb Bio's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Climb Bio Interest Expense Chart

Climb Bio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Climb Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CLYM
22GF Score
Climb Bio Inc CLYM
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Climb Bio Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of $0.00 Mil mean?
Climb Bio (CLYM) has a Interest Expense of $0.00 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Climb Bio and its competitors.
Is Climb Bio's Interest Expense too high?
Climb Bio's current Interest Expense is $0.00 Mil. Overall, Climb Bio has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Climb Bio's Interest Expense compare to XOMA and CTMX?
Climb Bio's Interest Expense of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Climb Bio and its competitors. Climb Bio's current Interest Expense is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Climb Bio stock overvalued right now?
Climb Bio (CLYM) has a current Interest Expense of $0.00 Mil. The current Interest Expense is $0.00 Mil. Climb Bio's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Climb Bio (CLYM), the current Interest Expense is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Climb Bio Business Description

Address 20 William Street, Suite 145, Wellesley Hills, MA, USA, 02481
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
22GF Score

Get the complete analysis for CLYM

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.90
Price